Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Common Equity (2016 - 2026)

Aytu Biopharma has reported Common Equity over the past 15 years, most recently at $14.2 million for Q4 2025.

  • Quarterly Common Equity fell 53.84% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2025, down 53.84% year-over-year, with the annual reading at $19.0 million for FY2025, 31.57% down from the prior year.
  • Common Equity was $14.2 million for Q4 2025 at Aytu Biopharma, down from $23.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $137.6 million in Q2 2021 and troughed at $14.2 million in Q4 2025.
  • The 5-year median for Common Equity is $34.9 million (2025), against an average of $47.9 million.
  • Year-over-year, Common Equity skyrocketed 11149900.0% in 2021 and then crashed 67.79% in 2022.
  • A 5-year view of Common Equity shows it stood at $105.5 million in 2021, then crashed by 56.59% to $45.8 million in 2022, then fell by 28.3% to $32.9 million in 2023, then fell by 6.36% to $30.8 million in 2024, then crashed by 53.84% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Common Equity are $14.2 million (Q4 2025), $23.2 million (Q3 2025), and $19.0 million (Q2 2025).